BioNTech announced a clinical trial collaboration and supply agreement with Gilead to evaluate pumitamig, a PD-L1/VEGF-A bispecific immunomodulator developed with BMS, in combination with Trodelvy for first-line locally advanced or metastatic PD-L1 low/negative TNBC. The alliance provides external validation and potential expansion of BioNTech's immuno-oncology portfolio, though clinical readouts and timelines remain uncertain.
BioNTech said it will shut production sites in Germany and Singapore after failing to secure buyers for pandemic-era manufacturing assets. The exits reflect a broader restructuring as the company pivots away from COVID-19 vaccine production, potentially lowering ongoing costs but also removing capacity tied to pandemic-era revenue streams. No financial details were disclosed.
BioNTech and OncoC4 reported PRESERVE-003 Stage 1 data for gotistobart (BNT316/ONC-392) showing OS of 18.5 months versus 10 months with docetaxel in squamous NSCLC after prior therapies. The pivotal stage 2 trial is underway at over 160 sites, and management frames these results as potentially transformative if replicated, which could uplift BNTX's oncology narrative ahead of pivotal data.
FDA approves supplemental BLA for Pfizer-BioNTech's XFG COVID-19 vaccine, a potential catalyst for BNTX. The report frames this amid other large-cap moves, suggesting regulatory news can lift vaccine names even with limited immediate price data. Investors should watch for translating factors such as orders, pricing, and rollout momentum that could lift BNTX sentiment.
BioNTech said it will terminate the Phase 2 trial of autogene cevumeran for resected colorectal cancer, a setback for its personalized cancer vaccine program. The news triggered a drop in BNTX shares and raises questions about the asset's contribution to near-term growth and the overall oncology pipeline. The outcome could recalibrate pipeline expectations and analyst price targets.
FDA approved the supplemental Biologics License Application for the 2026-27 COMIRNATY XFG vaccine targeting adults 65+ and high-risk 5-64. Shipping starts immediately, signaling near-term revenue potential as fall vaccination programs roll out. The XFG-adapted formulation aligns with FDA guidance, sustaining BioNTech’s COVID-19 vaccine franchise and its collaboration with Pfizer.
